Wordt geladen...
Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
The addition of rituximab to cyclophosphamide, vincristine and prednisolone (CVP) for advanced follicular lymphoma increases median time to progression by 17 months. A US societal cost-effectiveness of R-CVP versus CVP is estimated for a representative 50-year-old patient. Progression-free survival...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Informa Healthcare
2008
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2430747/ https://ncbi.nlm.nih.gov/pubmed/18231908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428190701769665 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|